Braveheart Bio (BRVE) will present two abstracts at the American Heart Association Scientific Sessions on November 6, 2026, in Chicago. A late-breaking presentation will cover 52-week extension data for BHB-1893 in obstructive hypertrophic cardiomyopathy. The other will address diastolic function in non-obstructive hypertrophic cardiomyopathy, drawing on laboratory studies and patients.
Braveheart Bio (BRVE) will host an investor and analyst webinar on its cardiac myosin inhibitor program on November 6, 2026.
The event runs from 4:35 p.m. to 6:05 p.m. ET and will cover global clinical development of BHB-1893 in obstructive and non-obstructive hypertrophic cardiomyopathy (HCM). Management and physicians Anjali Owens and Mariko Harper will speak, followed by a live question-and-answer session.
Braveheart Bio (BRVE) will participate in the Stifel Virtual Cardiometabolic Forum on September 30, 2026. Management is scheduled for a fireside chat that day at 12:30 p.m. EDT.
Interested parties can access a live webcast of the session via the News & Events section of the Braveheart Bio investor relations website at https://ir.braveheart.bio/. A replay of the webcast will be available in a temporary archive on the site after the event.
Braveheart Bio (BRVE) reported second quarter 2026 results and initiated its Phase 3 LIONHEART-HCM trial of BHB-1893 in obstructive hypertrophic cardiomyopathy.
Cash and cash equivalents were $122.8 million as of June 30, 2026, rising to an as-adjusted $527.3 million when including approximately $404.5 million in net proceeds from the August 2026 IPO. Management estimates this funding will support operations into 2029. The IPO issued 24,437,500 shares at $18.00 per share for gross proceeds of about $439.9 million.
R&D expenses grew to $11.1 million and G&A to $4.8 million, driving a quarterly net loss of $15.0 million, or $2.51 per share attributable to common stockholders after a non-cash deemed dividend. Phase 3 LIONHEART-HCM in oHCM is enrolling, with first dosing expected in 2026 and interim results in the second half of 2027, while a global Phase 3 NOBLEHEART-HCM trial in nHCM is planned for the first half of 2027 following favorable Phase 2 data.
Braveheart Bio (Nasdaq: BRVE), a clinical-stage biopharmaceutical company focused on hypertrophic cardiomyopathy and other serious cardiovascular diseases, will participate in the Cantor Global Healthcare Conference in New York, held September 9-11, 2026.
Management is scheduled for a fireside chat on Thursday, September 10, 2026 at 3:20 p.m. EDT. A live webcast and replay will be accessible via the News & Events section of Braveheart Bio’s investor relations website.
Braveheart Bio (Nasdaq: BRVE) closed its upsized initial public offering, selling an aggregate 24,437,500 common shares at $18.00 per share, including 3,187,500 additional shares from the underwriters’ option.
The offering generated gross proceeds of approximately $439.9 million before expenses. All shares were sold by Braveheart Bio. The stock began trading on the Nasdaq Global Market on August 6, 2026 under ticker “BRVE”. Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel and Cantor served as joint book-running managers. The registration statements became effective with the SEC on August 5, 2026.
Braveheart Bio (Nasdaq: BRVE) priced an upsized initial public offering of 21,250,000 common shares at $18.00 per share, all offered by the company. The shares are expected to begin trading on the Nasdaq Global Market on August 6, 2026, with closing anticipated on August 7, 2026, subject to customary conditions.
Braveheart Bio granted underwriters a 30‑day option to buy up to an additional 3,187,500 shares at the IPO price, less underwriting discounts and commissions. According to the company, expected gross IPO proceeds are about $382.5 million, excluding any exercise of this option. Goldman Sachs, Jefferies, TD Cowen, Stifel and Cantor are joint book‑running managers.